Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Rating of “Moderate Buy” from Brokerages

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has received a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $7.40.

A number of research firms have recently weighed in on ATNM. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a research note on Friday, November 15th. StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, Stephens reissued an “overweight” rating and issued a $5.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, November 19th.

Actinium Pharmaceuticals Price Performance

Shares of Actinium Pharmaceuticals stock opened at $1.44 on Wednesday. Actinium Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $10.24. The company has a market cap of $44.92 million, a P/E ratio of -1.04 and a beta of 0.07. The business has a fifty day moving average price of $1.46.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Rhumbline Advisers increased its position in Actinium Pharmaceuticals by 23.4% in the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of Actinium Pharmaceuticals in the 2nd quarter worth $92,000. Bank of New York Mellon Corp increased its holdings in shares of Actinium Pharmaceuticals by 28.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after buying an additional 19,035 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Actinium Pharmaceuticals during the 2nd quarter valued at about $142,000. Finally, Interchange Capital Partners LLC bought a new position in shares of Actinium Pharmaceuticals in the 3rd quarter valued at about $37,000. 27.50% of the stock is owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).